Lung disease is no longer something only older people or heavy smokers have to worry about. From polluted city air to complications after COVID‑19, people of many ages and backgrounds can be affected. Around the world:
- More than 500 million people live with chronic respiratory diseases.
- Diseases such as chronic obstructive pulmonary disease (COPD), asthma, pulmonary fibrosis, and lung cancer are major causes of illness and death worldwide.
- Air pollution alone is linked to around 7 million deaths every year.
When lung disease and its complications aren’t treated effectively, the impact on daily life—breathing, energy, freedom of movement—can become severe. While there are treatments available, many patients still feel there are gaps. That’s where LuciNinted aims to make a difference. With modern science and a patient‑centred approach, Lucius Pharmaceutical is providing a new option for people seeking hope and help.
What is LuciNinted?
LuciNinted is an oral (by mouth) medication offered in two strengths: 150 mg and 100 mg. It is supplied in a bottle of 60 tablets and is manufactured by Lucius Pharmaceutical. It requires a prescription from a doctor.
Originally known by the generic name nintedanib, this medicine works by blocking specific enzymes (so‑called tyrosine kinases) that are involved in the growth of fibrous (scar) tissue and new blood vessels. By doing so, it helps slow the progression of certain lung‑scarring diseases and some cancers.
What conditions can it treat?
LuciNinted is used for:
- Progressive fibrosing interstitial lung diseases (ILDs) including idiopathic pulmonary fibrosis (IPF) — a disease where lung tissue becomes scarred and breathing gradually worsens.
- Systemic sclerosis‑associated interstitial lung disease (SSc‑ILD), where lung fibrosis occurs in the context of scleroderma.
- In some settings, it may also have a role in certain types of lung cancer as part of combination therapy.
How does it help?
Here’s how LuciNinted supports patients:
- It reduces the decline in lung function: In patients with IPF and other progressive fibrosing ILDs, clinical trials show that nintedanib slows the annual decline in Forced Vital Capacity (FVC), a key measure of how well lungs work.
- The benefit persists over time: Continued use can help maintain lung function more steadily across years.
- It works across disease stages: Even patients with milder disease (still preserved lung volumes) may benefit.
- It lowers the risk of acute worsening (“exacerbations”) of lung fibrosis—serious events that may accelerate lung damage.
Safety and tolerability
- The safety profile of nintedanib is well‑established, with no new major safety signals emerging in long‑term use across many patient groups.
- The most common side effect is diarrhea (typically mild to moderate). Others include nausea, vomiting, elevated liver enzymes, decreased appetite and weight loss.
- Because it is processed by the liver and affects liver enzymes, regular monitoring of liver function is important.
- High treatment adherence is possible: Many patients are able to stay on the therapy long term, which is crucial for chronic progressive diseases.
How to take LuciNinted
- Take with food – A full meal helps absorption and can reduce gastrointestinal side‑effects like nausea or diarrhea.
- Twice daily, about 12 hours apart – e.g., 8:00 AM and 8:00 PM. Ensures more stable levels in the body.
- Swallow capsules whole – Do not chew, crush or open the capsules. If capsule contents touch skin, wash hands because they may irritate.
- If you miss a dose – Skip it and take the next one at the usual scheduled time. Do not double up to make up for the missed dose.
- Do not stop suddenly without medical advice – Abrupt discontinuation may allow disease progression to accelerate. Always consult your doctor before making changes.
Why choose LuciNinted by Lucius Pharmaceutical?
At Lucius Pharmaceutical, we are committed to delivering effective, safe and globally accessible therapies for patients in need. LuciNinted brings together cutting‑edge drug science (nintedanib) with our global partnerships to help make a meaningful difference for people affected by fibrotic lung disease and certain cancers. The availability in two strengths (150 mg and 100 mg) allows for treatment flexibility. Moreover, worldwide collaborations mean Lucius can help bring this therapy to many countries, improving access to patients who need it.
Important reminders
- This medication is prescription only. Your physician will decide whether LuciNinted is right for you, based on your specific type of disease, lung function, other health conditions and lab tests.
- Please inform your doctor of all medications you are taking, as drug interactions may exist.
- Ensure that liver function tests and other necessary labs are checked regularly while on treatment.
- Report any side effects or new symptoms (such as increased shortness of breath, coughing, changes in appetite, diarrhea) to your healthcare provider promptly.
- Keep lifestyle factors in mind: Although LorciNinted supports treatment, avoiding exposure to air pollutants, smoking cessation (if relevant), healthy diet, regular follow‑up and lung rehabilitation all help optimise outcomes.
